Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Off-Label Medicines Use: Complex Problem of Modern Clinical Practice

https://doi.org/10.20996/1819-6446-2020-04-14

Full Text:

Abstract

World experience in off-label medicines use is presented in the article. Data on the history of changes in tactics and approaches to solve the problem of medicines off-label use in the USA and some European countries, as well as in the European Union as a whole, are presented. The reasons, why doctors should use medicines off-label, are discussed. The expert opinion on the conditions ensuring the maximum safety in off-label medicines use is presented. In particular, the validity of obtaining patient informed consent is discussed. The article does not apply to the Russian regulation regarding “off-label” therapy but describes the foreign practice related to off-label medicines use. In addition, the results of some recently completed randomized clinical trials evaluating the effects of direct oral anticoagulants are presented in order to demonstrate the need to clarify the effectiveness and safety of medicines used in certain clinical situations. The results of such studies clarify the indications for the drug use, which are subsequently entered into the summary of product characteristics.

About the Author

S. R. Gilyarevskiy
Russian Medical Academy of Continuing Professional Education
Russian Federation

Sergey R. Gilyarevskiy – MD, PhD, Professor, Chair of Clinical Pharmacology and Therapy

Barrikadnaya ul. 2/1, Moscow, 125993



References

1. Order of the Ministry of Health of the Russian Federation (Ministry of Health of the Russian Federation) dated January 14, 2019 No. 4n “On approval of the procedure for prescribing drugs, prescription forms for drugs, the procedure for filling out these forms, their accounting and storage” Published on the official online portal of legal information 27.03 .19 g. [Cited 04/01/2020]. Available at: https://rg.ru/2019/03/29/minzdrav-prikaz4-site-dok.html (In Russ.)

2. Kalil A.C. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020 Mar 24. DOI:10.1001/jama.2020.4742. [Epub ahead of print].

3. Chen Z., Hu J., Zhang Z., et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. [cited by April 01, 2020]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3. DOI:10.1101/2020.03.22.20040758.

4. European Medicines Agency, Guideline on good pharmacovigilance practices, Module VI - Management and reporting of adverse reactions to medicinal products. [cited by April 01, 2020]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilancepractices-module-vi-management-reporting-adverse-reactions_en-0.pdf , para VI.A.2.1.2.

5. Bauman N.L., Sandefur C. Restoring Free Speech in Medicine: How state lawmakers can overcome FDA regulations that keep doctors and payers in the dark. Goldwater Institute, at 3, June 6, 2017 [cited by April 01, 2020]. Available from: https://ssrn.com/abstract=2982168.

6. O’Reilly J., Dalal A. Off label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law. 2003;12(2):295-324.

7. Mello M., Studdert D.M., Brennan T.A. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med. 2009;360(15):1557-66. DOI:10.1056/NEJMhle0807695.

8. Code of Federal Regulations. 21CFR312.2. Investigational new drug application [cited by April 01, 2020]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.2.

9. Ventola C.L. Off-label drug information: regulation, distribution, evaluation, and related controversies. P T. 2009;34(8):428-40.

10. Mithani Z. Informed consent for off-label use of prescription medications. Virtual Mentor. 2012;14(7):576-81. DOI:10.1001/virtualmentor.2012.14.7.oped1-1207.

11. Meadows W.A., Hollowell B.D. “Off-label” drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res. 2008;20(2):135-44. DOI:10.1038/sj.ijir.3901619.

12. Fitzgerald A.S., O’Malley P.G. Staying on track when prescribing off-label. Am Fam Physician. 2014;89:4-5.

13. Wittich C.M., Burkle C.M., Lanier W.L. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90. DOI:10.1016/j.mayocp.2012.04.017.

14. Gazarian M., Kelly M., McPhee J.R., et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8. DOI:10.5694/j.1326-5377.2006.tb00689.

15. Radley D.C., Finkelstein S.N., Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-6. DOI:10.1001/archinte.166.9.1021.

16. Shah S.S., Hall M., Goodman D.M., et al. Off-label Drug Use in Hospitalized Children. Arch Pediatr Adolesc Med. 2007;161(3):282-90. DOI:10.1001/archpedi.161.3.282.

17. Qureshi Z.P., Liu Y., Sartor O., et al. Enforcement actions involving Medicaid fraud and abuse, 1996- 2009. Arch Intern Med. 2011;171(8):785-7. DOI:10.1001/archinternmed.2011.142.

18. Chen H., Reeves J.H., Fincham J.E., et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67:972- 82. DOI:10.4088/jcp.v67n0615.

19. Lat I., Micek S., Janzen J., et al. Off-label medication use in adult critical care patients. J Crit Care. 2011;26:89-94. DOI:10.1016/j.jcrc.2010.06.012.

20. Lin H.W., Phan K., Lin S.J. Trends in off-label beta-blocker use: a secondary data analysis. Clin Ther. 2006;28(10):1736-46. DOI:10.1016/j.clinthera.2006.10.015.

21. Loder E.W., Biondi D.M. Off-label prescribing of drugs in specialty headache practice. Headache. 2004;44:636-41. DOI:10.1111/j.1526-4610.2004.04121.x.

22. Picard D., Carvalho P., Bonnavia C., et al. Evaluation des prescriptions hors AMM en Dermatologie [Assessment off-label prescribing in dermatology]. Ann Dermatol Venereol. 2003;130: 507-10. DOI:AD-05-2003-130-5-0151-9638-101019-ART3.

23. Ratner M. Pfizer settles largest ever fraud suit for off-label promotion. Nat Biotechnol. 2009;27(11):961-2. DOI:10.1038/nbt1109-961.

24. Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ. 2009;338:b217. DOI:10.1136/bmj.b217.

25. Weda M., Hoebert J., Vervloet M., et al. Study on off-label use of medicinal products in the European (2019) [cited by April 01, 2020]. Available from: https://op.europa.eu/en/publication-detail/-/publication/ecf85518-d376-11e9-b4bf-01aa75ed71a110.2875/464022.

26. Schrier L., Hadjipanayis A., Stiris T., et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020;179(5):839- 847. DOI:10.1007/s00431-019-03556-9.

27. Lenk C., Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag. 2014;10:537-46. DOI:10.2147/TCRM.S40232.

28. Aronson J.K., Ferner R.E. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. Br J Clin Pharmacol. 2017;83:2615-25. DOI:10.1111/bcp.13394.

29. Stafford R.S. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-9. DOI:10.1056/NEJMp0802107.

30. França K., Litewka S. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies. Int J Dermatol. 2019;58:788-94. DOI:10.1111/ijd.14222.

31. Oliphant C.S., Owens R.E., Bolorunduro O.B., Jha S.K. Ivabradine: A Review of Labeled and Off-Label Uses. Am J Cardiovasc Drugs. 2016;16:337-47. DOI:10.1007/s40256-016-0178-z.

32. Schulze V., Steiner S., Hennersdorf M., Strauer B.E. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology. 2008;110:206-8. DOI:10.1159/000111931.

33. Retegui G., Quintero M., Ruiz-Borrell M., Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol. 2009;62:576-88. DOI:10.1016/s1885-5857(09)71843-2.

34. Winum P.F., Cayla G., Rubini M., et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. PACE. 2009;32:942-4. DOI:10.1111/j.1540-8159.2009.02414.x.

35. Settle A., Martino A., Lioy E., Calo L. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol. 2010;21:815-7. DOI:10.1111/j.1540-8167.2009.01699.x.

36. Goyal V.K., Godara S., Sadasukhi T.C., Gupta H.L. Management of inappropriate sinus tachycardia with ivabradine in a renal transplant recipient. Drug Discov Ther. 2014;8:132-3. DOI:10.5582/ddt.2014.01023.

37. Zellerhoff S., Hinterseer M., Felix Krull B., et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(5-6):483-6. DOI:10.1007/s00210-010-0565-y.

38. Calo L., Rebecchi M., Sette A., et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318-23. DOI:10.1016/j.hrthm.2010.05.034.

39. Benezet-Mazuecos J., Rubio J.M., Farre J., et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE. 2013;36:830-6. DOI:10.1111/pace.12118.

40. Ptaszynski P., Kaczmarek K., Ruta J., et al. Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofrequency catheter ablation of atrioventricular node slow pathway. PACE. 2013;36:42-9. DOI:10.1111/pace.12018

41. Boeken U., Assmann A., Mehdiani A., et al. Ivabradine in patients with inappropriate sinus tachycardia after cardiac surgery: alternative to b-blockers? Thorac Cardiovasc Surg. 2012;60:119. DOI:10.1055/s-0031-1297766.

42. Cappato R., Castelvecchio S., Ricci C., et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323-9.DOI:10.1016/j.jacc.2012.06.031.

43. Ptaszynski P., Kaczmarek K., Ruta J., et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15:116—121. DOI:10.1093/europace/eus204.

44. Ptaszynski P., Kaczmarek K., Ruta J., et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338-44. DOI:10.1177/1074248413478172.

45. Sheldon R.S., Grubb B.P. II, Olshansky B., et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm. 2015;12:e41-63. DOI:10.1016/j.hrthm.2015.03.029.

46. Frattarelli D.A., Galinkin J.L., Green T.P., et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014;133:563-7. DOI:10.1542/peds.2013-4060.

47. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med. 1997;337:581-8. DOI:10.1056/NEJM199708283370901.

48. Friedman M.A., Woodcock J., Lumpkin M.M., et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728-34. DOI:10.1001/jama.281.18.1728.

49. Cheng W.H., Chao T.F., Lin Y.J., et al. Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. Stroke. 2019;50:2574-7. DOI:10.1161/STROKEAHA.119.025623.

50. Paciaroni M., Agnelli G., Caso V., et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019;50(8):2168-74. DOI:10.1161/STROKEAHA.119.025350.

51. Santos J., António N., Rocha M., Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol. 2019 Oct 20. DOI:10.1111/bcp.14127. [Epub ahead of print].

52. Noel N., Dutasta F., Costedoat-Chalumeau N., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14(8):680-5. DOI:10.1016/j.autrev.2015.03.007.

53. Cohen H., Hunt B.J., Efthymiou M., et al.; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3(9):e426-436. DOI:10.1016/S2352-3026(16)30079-5.

54. Ordi-Ros J., Sáez-Comet L., Pérez-Conesa M., et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med 2019 Oct 15. DOI:10.7326/M19-0291. [Epub ahead of print].

55. Konstantinides S.V., Meyer G., Becattini C., et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. DOI:10.1093/eurheartj/ehz405.

56. Pokorney S.D. American College of Cardiology Webpage, AHA 2019 Presentation Slides for the RENAL-AF Trial [cited by April 01, 2020]. Available from: https://www.acc.org/education-andmeetings/image-and-slide-gallery/media-detail?id=469e5bd88-f4d2bb8ec183e71521637.

57. Reinecke H., Jurgensmeyer S., Engelbertz C., et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: The AXADIA-AFNET 8 study. BMJ Open. 2018;8(9):e022690. DOI:10.1136/bmjopen-2018-022690.

58. Noseworthy P.A., Kaufman E.S., Chen L.Y., et al. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation. 2019;140(25):e944-e963. DOI:10.1161/CIR.0000000000000740.

59. Lopes R.D., Alings M., Connolly S.J., et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-45. DOI:10.1016/j.ahj.2017.04.008.

60. Kirchhof P., Blank B.F., Calvert M., et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12-8. DOI:10.1016/j.ahj.2017.04.015.

61. Hart R.G., Sharma M., Mundl H., et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018;378(23):2191-201. DOI:10.1056/NEJMoa1802686.

62. Diener H.C., Sacco R.L., Easton J.D., et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019;380(20):1906-17. DOI:10.1056/NEJMoa1813959.

63. Busko M. Rivaroxaban May Reduce Stroke After ESUS With Large Left Atrium [cited by April 01, 2020]. Available from: https://www.medscape.com/viewarticle/904151.

64. Kamel H., Longstreth W.T. Jr, Tirschwell D.L., et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019;14(2):207-14. DOI:10.1177/1747493018799981.

65. Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219-30. DOI:10.1160/TH16-08-0615.

66. Lyman G.H., Bohlke K., Falanga A., American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442-e444. DOI:10.1200/JOP.2015.004473.

67. Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-52. DOI:10.1016/j.chest.2015.11.026.

68. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146- 53. DOI:10.1056/NEJMoa025313.

69. Lee A.Y.Y., Kamphuisen P.W., Meyer G., Bauersachs R., et al.; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-86. DOI:10.1001/jama.2015.9243.

70. Raskob G.E., van Es N., Verhamme P., et al.; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378:615-24. DOI:10.1056/NEJMoa1711948.

71. Agnelli G., Becattini C., Meyer G., et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Mar 29. DOI:10.1056/NEJMoa1915103. [Epub ahead of print].


For citation:


Gilyarevskiy S.R. Off-Label Medicines Use: Complex Problem of Modern Clinical Practice. Rational Pharmacotherapy in Cardiology. 2020;16(2):324-334. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-14

Views: 184


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)